Yingying Sun1, Chunyan Liu1, Ting Jiao1, Ning Xie1, Huaquan Wang1, Weiwei Qi1, Zonghong Shao2. 1. Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin, China. 2. Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin, China. sun12345yingying@163.com.
Abstract
OBJECTIVE: To investigate the expression of lymphocyte activation gene 3(LAG3) on CD8+T effector cells (Teffs), CD4+ Teffs and regulatory T cells (Tregs) in patients with severe aplastic anemia (SAA). METHODS: We detected the expression of LAG3 on CD8+ Teffs, CD4+ Teffs and Tregs in SAA patients and healthy controls (HC) by flow cytometry, and analyzed its correlation with the immune status and severity of the disease. ELISA was used to detect soluble LAG3(sLAG3). RESULTS: The expression of LAG3 on CD8+ Teffs, CD4+ Teffs and Tregs in untreated SAA patients were significantly lower than those in HC group (P < 0.05). After IST, the LAG3 expression of target cells increased to a level even higher than that in HC group (P < 0.05). LAG3 on T cell subsets was closely related to immune status and severity of the disease. The concentration of sLAG3 in these groups showed similar trends. LAG3 was not a prognostic factor of response. CONCLUSION: The decreased expression of LAG3 on CD8+ Teffs, CD4+ Teffs and Tregs may be involved in the pathogenesis of SAA. LAG3 intervention may have therapeutic potential in treating SAA.
OBJECTIVE: To investigate the expression of lymphocyte activation gene 3(LAG3) on CD8+T effector cells (Teffs), CD4+ Teffs and regulatory T cells (Tregs) in patients with severe aplastic anemia (SAA). METHODS: We detected the expression of LAG3 on CD8+ Teffs, CD4+ Teffs and Tregs in SAA patients and healthy controls (HC) by flow cytometry, and analyzed its correlation with the immune status and severity of the disease. ELISA was used to detect soluble LAG3(sLAG3). RESULTS: The expression of LAG3 on CD8+ Teffs, CD4+ Teffs and Tregs in untreated SAA patients were significantly lower than those in HC group (P < 0.05). After IST, the LAG3 expression of target cells increased to a level even higher than that in HC group (P < 0.05). LAG3 on T cell subsets was closely related to immune status and severity of the disease. The concentration of sLAG3 in these groups showed similar trends. LAG3 was not a prognostic factor of response. CONCLUSION: The decreased expression of LAG3 on CD8+ Teffs, CD4+ Teffs and Tregs may be involved in the pathogenesis of SAA. LAG3 intervention may have therapeutic potential in treating SAA.
Entities:
Keywords:
Anemia, Aplastic; CD4+ T effector cells; CD8+ T effector cells; LAG3; Regulatory T cells
Authors: Judith C W Marsh; Sarah E Ball; Jamie Cavenagh; Phil Darbyshire; Inderjeet Dokal; Edward C Gordon-Smith; Jane Keidan; Andrew Laurie; Anna Martin; Jane Mercieca; Sally B Killick; Rhona Stewart; John A L Yin Journal: Br J Haematol Date: 2009-08-10 Impact factor: 6.998
Authors: Feng Xu; Jing Liu; Di Liu; Biao Liu; Min Wang; Zhiyuan Hu; Xuemei Du; Li Tang; Fuchu He Journal: Cancer Res Date: 2014-04-25 Impact factor: 12.701
Authors: Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali Journal: Cancer Res Date: 2011-12-20 Impact factor: 12.701
Authors: Maria Bettini; Andrea L Szymczak-Workman; Karen Forbes; Ashley H Castellaw; Mark Selby; Xiaoyu Pan; Charles G Drake; Alan J Korman; Dario A A Vignali Journal: J Immunol Date: 2011-08-26 Impact factor: 5.422
Authors: Nicholas M Durham; Christopher J Nirschl; Christopher M Jackson; Jimmy Elias; Christina M Kochel; Robert A Anders; Charles G Drake Journal: PLoS One Date: 2014-11-05 Impact factor: 3.240